Military Health Research Foundation Inc is located in Laurel, MD. The organization was established in 2011. According to its NTEE Classification (U40) the organization is classified as: Engineering & Technology, under the broad grouping of Science & Technology and related organizations. As of 12/2022, Military Health Research Foundation Inc employed 13 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Military Health Research Foundation Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2022, Military Health Research Foundation Inc generated $5.7m in total revenue. This organization has experienced exceptional growth, as over the past 8 years, it has increased revenue by an average of 13.7% each year . All expenses for the organization totaled $6.0m during the year ending 12/2022. While expenses have increased by 14.4% per year over the past 8 years. They've been increasing with an increasing level of total revenue. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
THE MILITARY HEALTH RESEARCH FOUNDATION(MHRF) IS A 501(C)(3) NONPROFIT ORGANIZATION DEDICATED TO THE ADVANCEMENT OF MILITARY MEDICAL RESEARCH TO BENEFIT THE HEALTH AND SAFETY OF THE MEN AND WOMEN OF THE UNITED STATES ARMED FORCES.
Describe the Organization's Program Activity:
Part 3 - Line 4a
MEDICAL DEVICE DEVELOPMENT RESEARCH - MHRF CONDUCTS MEDICAL DEVICE RESEARCH FOR THE MILITARY PRIMARILY FOCUSED ON DEALING WITH TRAUMA, VASCULAR INJURY, RESUSCITATION AND OTHER COMBAT CARE TREATMENTS WHICH INCLUDE THE FOLLOWING PROJECTS: ENDOVASCULAR PERFUSION AUGMENTATION FOR CRITICAL CARE - MHRF HAS BEEN AWARDED A COOPERATIVE AGREEMENT FOR THE PERSONALIZED AND ADAPTIVE THERAPY FOR RESUSCITATION AFTER TRAUMA. THIS AGREEMENT PROVIDES FOR THE RESEARCH AND DEVELOPMENT OF INNOVATIVE PATIENT-CENTERED TECHNOLOGIES TO MAINTAIN PHYSIOLOGICAL EQUILIBRIUM IN AN EFFORT TO MINIMIZE PREVENTABLE DEATHS FOR CRITICALLY ILL WARFIGHTERS BY EMPLOYING PERSONALIZED, GOAL-DIRECTED PRECISION CRITICAL CARE SUPPORT IN WAYS THAT WERE NEVER BEFORE POSSIBLE. VENTRIGHT - MHRF HAS BEEN AWARDED A COOPERATIVE AGREEMENT FOR THE RESEARCH AND DEVELOPMENT OF A PORTABLE VENTILATION MONITORING OPTIMIZING CRITICAL CARE DEVICE FROM THE DEPARTMENT OF DEFENSE IN SUPPORT OF THE AIR FORCE MATERIEL COMMAND. THE OBJECTIVE OF THIS EFFORT IS TO DEVELOP: (A) A BATTERY-OPERATED DEVICE CAPABLE OF COLLECTING AND INTEGRATING VENTILATION AND PHYSIOLOGIC METRICS; (B) DIAGNOSTIC ALGORITHMS CAPABLE OF IDENTIFYING COMMON CRITICAL RESPIRATORY DISEASE STATES AND SUB-OPTIMAL VENTILATION; AND (C) INTEGRATION OF THE DEVICE WITH THE ALGORITHMS TO CREATE A ROBUST AND PORTABLE VENTILATION ANALYTICS MONITOR CAPABLE OF BATTLEFIELD DEPLOYMENT. EVAC - MHRF IS RESEARCHING THE DEVELOPMENT OF THE DESIGN OF A CLINICAL-GRADE EVAC CONTROLLER FOR PROLONGED WEANING TO PROVIDE PARTIAL FLOW WHICH WILL LEAD TO THE DEVELOPMENT OF HARDWARE AND SOFTWARE FOR TEST FIXTURES NEEDED FOR THE EVAC CONTROLLER MANUFACTURING, VERIFICATION AND VALIDATION TESTING AS WELL AS MANUFACTURING OF STERILE UNITS IN FINAL PACKAGING FOR THE VERIFICATION AND VALIDATION AND COMPLETION OF REGULATORY DOCUMENTATION FOR THE EVAC CONTROLLER.
LABORATORY AND ANIMAL RESEARCH - MHRF IS PERFORMING LABORATORY AND ANIMAL SCIENTIFIC RESEARCH AND EXPERIMENTS TO AID IN THE ADVANCEMENT OF MILITARY TECHNOLOGY AND MILITARY RESEARCH TO BENEFIT THE UNITED STATES ARMED FORCES WHICH INCLUDE THE FOLLOWING PROJECTS: UMD EPR - MHRF IS CONDUCTING WORK FOR THE UNIVERSITY OF MARYLAND, BALTIMORE CAMPUS TO INVESTIGATE EMERGENCY PRESERVATION AND RESUSCITATION (EPR) TECHNOLOGY IN THE CONTEXT OF AUTONOMOUS TRANSPORT. THE FIRST AIM IS TO CHARACTERIZE THE PHYSIOLOGIC RESPONSE TO EXTRA-CORPOREAL MEMBRANE OXYGENATION (ECMO) ACHIEVED EPR IN MODELS OF CONTROLLED YET CRITICAL PHYSIOLOGIC DERANGEMENT. THE SECOND AIM IS THE GENERATION OF CLOSED LOOP CONTROL ALGORITHMS TO AUTOMATE EMCO.SUCCOR COMBAT FOAM FOR LARGE BURN WOUNDS - MHRF LEAD A PROOF-OF-CONCEPT EVALUATION OF FINAL SUCCORTM FORMULATION COMPARED TO STANDARD OF CARE SILVER-CONTAINING DRESSINGS IN A COMBAT-RELEVANT ANIMAL MODEL OF INFECTED DEEP-PARTIAL THICKNESS THERMAL BURN WOUNDS HEALING IN THE ABSENCE OF GRAFTING. THE LARGE-ANIMAL SAFETY AND EFFICACY TESTING WAS PERFORMED WITH THE OREGON HEALTH & SCIENCE UNIVERSITY SCHOOL OF MEDICINE IN A LARGE-ANIMAL LABORATORY. EYE AID SYSTEM FOR ACUTE OCULAR THERAPIES - IN ALMOST ALL CASES, EFFICACY STUDIES SUPPORTING AN FDA REGULATORY SUBMISSION NEED TO BE PERFORMED UNDER GLP WITH A FINAL HUMAN-USABLE CGMP DEVICE. EARLIER-STAGE EFFICACY TESTING PRIOR TO LOCKING IN CGMP DEVICE PRODUCTION CAN HELP REDUCE REGULATORY AND PROGRAMMATIC RISK. MHRF PERFORMED ANIMAL EFFICACY STUDIES WITH OREGON HEALTH & SCIENCE UNIVERSITY TO GENERATE PERFORMANCE DATA AND REDUCE THE RISKS. MITOCHONDRIA - THERE ARE SEVERAL DISEASES INCLUDING TRAUMA AND HEMORRHAGE THAT ADVERSELY AFFECT THE MITOCHONDRIA OF THE BODY. MHRF IS WORKING WITH AN INVESTIGATOR FROM THE UNIVERSITY OF UTAH TO STUDY THE USE OF ELAMIPRETIDE, AS A MOLECULE TO REDUCE COMPLICATIONS ASSOCIATED WITH THE USE OF RESUSCITATIVE ENDOVASCULAR BALLOON OCCLUSION OF THE AORTA (REBOA) IN A PIG MODEL OF SEVERE BLOOD LOSS. THIS EXPERIMENT WILL DEMONSTRATE THAT ELAMIPRETIDE CAN PREVENT COMPLICATIONS COMMONLY OBSERVED AFTER USING REBOA CATHETERS.
OTHER PROGRAM SERVICES - MHRF ALSO PROVIDES ENTERPRISE, PROGRAM, AND PROJECT LEVEL RESEARCH ADMINISTRATION AND PROVIDES SOLUTIONS TO SPECIFIC TASKINGS SUCH AS RESEARCH PROCESS CONSULTING, STAFFING SUPPORT, AND CLINICAL TRIALS WHICH INCLUDE THE FOLLOWING PROJECTS: PE SYSTEMS CONDUCTS ACQUISITION AND PROTOTYPING SUPPORT FOR THE UNITED STATES AIR FORCE. MHRF PROVIDES A PROJECT LEVEL SUBJECT MATTER EXPERT THAT SERVES AT THE LIFE CYCLE MANAGEMENT GROUP FOR THE HUMAN SYSTEMS DIVISION.CDC EAGLE GLOBAL SCIENTIFIC IS A LIFE SCIENCES COMPANY THAT PROVIDES RESEARCH, DEVELOPMENT, AND PERSONNEL SUPPORT TO MANY FEDERAL AGENCIES. MHRF PROVIDES AN EPIDEMIOLOGIST THAT WORKS DIRECTLY AT THE CENTERS FOR DISEASE CONTROL. ZEISS CRADA: MHRF PROVIDES A CLINICAL RESEARCH ASSISTANT WHO WORKS AT THE REFRACTIVE SURGERY CENTER LOCATED IN THE WILFORD HALL AMBULATORY SURGICAL CENTER AT LACKLAND AIR FORCE BASE.
Name (title) | Role | Hours | Compensation |
---|---|---|---|
Ramsey Taweel President/ceo | OfficerTrustee | 40 | $219,972 |
Theresa Casey Director | Trustee | 1 | $0 |
Lawerence Diamond Director | Trustee | 1 | $0 |
Steve Mcanallen Director | Trustee | 1 | $0 |
James Ross Chief Scientist | Officer | 40 | $331,380 |
Todd Graham Director Of Laboratory Ops | 40 | $175,181 |
Vendor Name (Service) | Service Year | Compensation |
---|---|---|
Tom Gardner Consulting | 12/30/16 | $183,337 |
Mark Lyles Consulting | 12/30/16 | $149,500 |
Statement of Revenue | |
---|---|
Federated campaigns | $0 |
Membership dues | $0 |
Fundraising events | $0 |
Related organizations | $0 |
Government grants | $3,892,810 |
All other contributions, gifts, grants, and similar amounts not included above | $0 |
Noncash contributions included in lines 1a–1f | $0 |
Total Revenue from Contributions, Gifts, Grants & Similar | $3,892,810 |
Total Program Service Revenue | $1,841,635 |
Investment income | $105 |
Tax Exempt Bond Proceeds | $0 |
Royalties | $0 |
Net Rental Income | $0 |
Net Gain/Loss on Asset Sales | $0 |
Net Income from Fundraising Events | $0 |
Net Income from Gaming Activities | $0 |
Net Income from Sales of Inventory | $0 |
Miscellaneous Revenue | $0 |
Total Revenue | $5,734,550 |
Statement of Expenses | |
---|---|
Grants and other assistance to domestic organizations and domestic governments. | $0 |
Grants and other assistance to domestic individuals. | $0 |
Grants and other assistance to Foreign Orgs/Individuals | $0 |
Benefits paid to or for members | $0 |
Compensation of current officers, directors, key employees. | $220,000 |
Compensation of current officers, directors, key employees. | $50,268 |
Compensation to disqualified persons | $0 |
Other salaries and wages | $949,484 |
Pension plan accruals and contributions | $54,211 |
Other employee benefits | $156,829 |
Payroll taxes | $75,342 |
Fees for services: Management | $0 |
Fees for services: Legal | $6,903 |
Fees for services: Accounting | $83,732 |
Fees for services: Lobbying | $0 |
Fees for services: Fundraising | $0 |
Fees for services: Investment Management | $0 |
Fees for services: Other | $287,603 |
Advertising and promotion | $55,800 |
Office expenses | $46,239 |
Information technology | $13,000 |
Royalties | $0 |
Occupancy | $18,301 |
Travel | $61,222 |
Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
Conferences, conventions, and meetings | $2,600 |
Interest | $0 |
Payments to affiliates | $0 |
Depreciation, depletion, and amortization | $1,220 |
Insurance | $5,334 |
All other expenses | $0 |
Total functional expenses | $5,971,452 |
Balance Sheet | |
---|---|
Cash—non-interest-bearing | $218,123 |
Savings and temporary cash investments | $197,401 |
Pledges and grants receivable | $1,025,658 |
Accounts receivable, net | $0 |
Loans from Officers, Directors, or Controlling Persons | $0 |
Loans from Disqualified Persons | $0 |
Notes and loans receivable | $0 |
Inventories for sale or use | $0 |
Prepaid expenses and deferred charges | $3,246 |
Net Land, buildings, and equipment | $0 |
Investments—publicly traded securities | $0 |
Investments—other securities | $0 |
Investments—program-related | $0 |
Intangible assets | $0 |
Other assets | $0 |
Total assets | $1,444,428 |
Accounts payable and accrued expenses | $969,853 |
Grants payable | $0 |
Deferred revenue | $0 |
Tax-exempt bond liabilities | $0 |
Escrow or custodial account liability | $0 |
Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
Secured mortgages and notes payable | $0 |
Unsecured mortgages and notes payable | $0 |
Other liabilities | $0 |
Total liabilities | $969,853 |
Net assets without donor restrictions | $474,575 |
Net assets with donor restrictions | $0 |
Capital stock or trust principal, or current funds | $0 |
Paid-in or capital surplus, or land, building, or equipment fund | $0 |
Retained earnings, endowment, accumulated income, or other funds | $0 |
Total liabilities and net assets/fund balances | $1,444,428 |